LENSAR Inc LNSR 深 滬
交易中 02-09 10:50:53 美东时间
12.10
+0.020
+0.17%
華盛通- 最 高12.23
- 今 開12.05
- 成交量 9033股
- 最 低 12.05
- 昨 收 12.08
- 總市值 1.45亿
- 52周最高 17.31
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 8.96
- 委 比 99.82%
- 總股本 1194.45万
- 歷史最高 17.31
- 量 比 1.01
- 振 幅 1.49%
- 歷史最低 1.80
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LENSAR stockholders approve directors and auditor at meeting
An announcement from LENSAR ( ($LNSR) ) is now available. On December 18, 2025,...
2025-12-20 05:44
眼科巨头，密集并购
原标题：眼科巨头，密集并购 来源：动脉网 近期的眼科行业，热闹非凡。 自8月爱尔康官宣溢价51%收购STAAR Surgical至今，相关报道便霸榜眼科行业热...
2025-10-26 12:27
LENSAR Announces Virtual Annual Meeting Plans
An update from LENSAR ( ($LNSR) ) is now available. LENSAR, Inc. has announced ...
2025-10-22 05:06
LENSAR Q2 EPS $(0.15) Compared With $(0.79) YoY, Sales $13.935M Miss $16.550M Estimate
LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.02) by 650 percent. This is a 67.39 percent increase over losses of $(0.46) per share from the same
2025-08-07 19:28
107 亿！巨头溢价 59%收购昔日对手
（来源：CHC医疗传媒） 2025 年 8 月 5 日，全球眼科医疗巨头爱尔康（Alcon）宣布以 15 亿美元（约合107亿元人民币）收购纳斯达克上市公司...
2025-08-07 14:30
LENSAR Stockholders Approve Merger with Alcon Research
LENSAR ( ($LNSR) ) has issued an update. On July 2, 2025, LENSAR, Inc. held a v...
2025-07-03 04:17
快讯 | LENSAR根据纳斯达克上市规则5635(C)(4)报告诱导性授予
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-06-03 04:01
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. announced that a majority of its independent board members granted 3,090 restricted stock units (RSUs) to 10 newly-hired non-executive employees as an inducement for joining the Company. The RSUs vest over four years, contingent on continued employment. LENSAR, a medical device company, specializes in developing advanced systems like the ALLY Robotic Cataract Laser System, which integrates AI for improved surgical outcomes and effici...
2025-06-02 20:01
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
2025-05-30 01:28
FTC Extends Waiting Period for LENSAR Merger
LENSAR ( ($LNSR) ) just unveiled an update. On March 23, 2025, LENSAR, Inc. ent...
2025-05-23 05:12
